Your browser doesn't support javascript.
loading
Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?
Waitzberg, Dan; Guarner, Francisco; Hojsak, Iva; Ianiro, Gianluca; Polk, D Brent; Sokol, Harry.
Afiliación
  • Waitzberg D; Department of Gastroenterology, LIM-35, School of Medicine, University of São Paulo, São Paulo, Brazil.
  • Guarner F; Teknon Medical Centre, Barcelona, Spain.
  • Hojsak I; Referral Centre for Pediatric Gastroenterology and Nutrition, School of Medicine, University of Zagreb, Zagreb, Croatia.
  • Ianiro G; University of Zagreb Medical School, Zagreb, Croatia.
  • Polk DB; Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Sokol H; Department of Medical and Surgical Sciences, UOC Gastroenterologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Adv Ther ; 41(3): 901-914, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38286962
ABSTRACT
Dysbiosis corresponds to the disruption of a formerly stable, functionally complete microbiota. In the gut, this imbalance can lead to adverse health outcomes in both the short and long terms, with a potential increase in the lifetime risks of various noncommunicable diseases and disorders such as atopy (like asthma), inflammatory bowel disease, neurological disorders, and even behavioural and psychological disorders. Although antibiotics are highly effective in reducing morbidity and mortality in infectious diseases, antibiotic-associated diarrhoea is a common, non-negligible clinical sign of gut dysbiosis (and the only visible one). Re-establishment of a normal (functional) gut microbiota is promoted by completion of the clinically indicated course of antibiotics, the removal of any other perturbing external factors, the passage of time (i.e. recovery through the microbiota's natural resilience), appropriate nutritional support, and-in selected cases-the addition of probiotics. Systematic reviews and meta-analyses of clinical trials have confirmed the strain-specific efficacy of some probiotics (notably the yeast Saccharomyces boulardii CNCM I-745 and the bacterium Lactobacillus rhamnosus GG) in the treatment and/or prevention of antibiotic-associated diarrhoea in children and in adults. Unusually for a probiotic, S. boulardii is a eukaryote and is not therefore directly affected by antibiotics-making it suitable for administration in cases of antibiotic-associated diarrhoea. A robust body of evidence from clinical trials and meta-analyses shows that the timely administration of an adequately dosed probiotic (upon initiation of antibiotic treatment or within 48 h) can help to prevent or resolve the consequences of antibiotic-associated dysbiosis (such as diarrhoea) and promote the resilience of the gut microbiota and a return to the pre-antibiotic state. A focus on the prescription of evidence-based, adequately dosed probiotics should help to limit unjustified and potentially ineffective self-medication.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Probióticos / Lacticaseibacillus rhamnosus / Saccharomyces boulardii Tipo de estudio: Risk_factors_studies Límite: Adult / Child / Humans Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Probióticos / Lacticaseibacillus rhamnosus / Saccharomyces boulardii Tipo de estudio: Risk_factors_studies Límite: Adult / Child / Humans Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Brasil